Navigation Links
Slovenia's 1st Total Artificial Heart Patient Discharged from UMC Ljubljana Using the Freedom® Portable Driver
Date:1/19/2012

TUCSON, Ariz., Jan. 19, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the SynCardia temporary Total Artificial Heart, announced today that on Dec. 29, 2011, University Medical Center (UMC) Ljubljana discharged Slovenia's first Total Artificial Heart patient, 61-year-old Nikola Gaspic, to wait for a matching donor heart at home using the Freedom® portable driver.

(Photo: http://photos.prnewswire.com/prnh/20120119/LA37985)

"The Total Artificial Heart was the perfect solution to bridge this patient to a transplant because he had a ventricular septal defect (VSD). For VSD, there are no other effective treatments," said Dr. Ivan Knezevic, Director of the Transplant and Mechanical Circulatory Support Program in the Department of Cardiovascular Surgery at UMC Ljubljana.

Previously healthy, Mr. Gaspic suffered a heart attack that created a hole in his septum (VSD), which is the wall that separates the left and right ventricles of the heart. He was placed on inotropes and implanted with an intra-aortic balloon pump (IABP), but he continued to deteriorate. To save his life, on Oct. 19, 2011, doctors implanted the Total Artificial Heart as the only suitable treatment option.

The implant surgery was performed by Dr. Knezevic and proctored by experienced Total Artificial Heart surgeon Dr. Latif Arusoglu. It was the first implantation of SynCardia's Total Artificial Heart in southeastern Europe.

UMC Ljubljana is Slovenia's biggest hospital and its only transplant center. Each year, UMC Ljubljana performs 18-19 heart transplants and approximately 1,000 open heart surgeries. It is the first and only SynCardia Certified Center in Slovenia.

Weighing approximately 6 kg, the Freedom portable driver is the world's first wearable power supply for the SynCardia Total Artificial Heart. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

SynCardia recognizes and thanks Katarina Tepsic Stupica, PhD and Medica d.o.o., the Slovenian distributor for the Total Artificial Heart, for their commitment and on-going support of UMC Ljubljana.

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 950 implants of the Total Artificial Heart, accounting for more than 230 patient years of life.

Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers and does not require expensive anti-rejection medication, which can cause subsequent complications. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

SynCardia Ranked #20 Among World's 50 Most Innovative Companies

In March 2011, Fast Company magazine ranked SynCardia #20 in its annual list of the "World's 50 Most Innovative Companies" for "giving mobility to artificial heart recipients." Weighing 13.5 pounds, SynCardia's Freedom® portable driver is the world's first wearable driver designed to power the Total Artificial Heart both inside and outside the hospital. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

For up-to-date information, please visit: http://www.syncardia.com
Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn

 

 


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 40 High-Achieving Students with Cystic Fibrosis Receive $100,000 Total in Higher Education Scholarships From SolvayCARES(SM)
2. Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During Live Case at the Paris Cardiovascular Interventions Course (Francophone) 2008
3. Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xian Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinbas Total Profit
4. "Put Down the BBQ Ribs, We've Found You a Donor Heart," Nurse Tells Patient : Ohio Father near Death Gets Second Chance at Life with CardioWest™ temporary Total Artificial Heart
5. Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
6. New Radiation-Blocking Medical Garments Introduced at RSNA Meeting in Chicago : Demron-M Technology Provides Total Protection in a Lightweight, Durable, Flexible Fabric
7. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
8. Immune Targeting Systems Completes Second Tranche of Series-A Funding Bringing Total Funds Raised to More Than GBP5m
9. Abbott Employee Giving Sets New Records for Employee Participation and Total Donations
10. Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement
11. Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Calif. , Aug. 15, 2017 After spending the ... and support with crowdsourced data collection, GeneFo now offers this platform ... in aligning and amplifying support, adherence, and data collection vis a ... medical foundations mark the successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... ... August 15, 2017 , ... Pittcon is ... for analytical and scientific instruments. This year’s symposium, organized by the Pittcon 2018 ... Spectrometry for Bioanalytical Applications.” This dynamic presentation will discuss novel ionization processes, high ...
(Date:8/15/2017)... ... August 15, 2017 , ... The Conference Forum and ... programming through a series of upcoming panels and events. The partnership culminates with the ... Roosevelt Hotel in New York City. , “With our experience in producing the Immuno-Oncology ...
(Date:8/14/2017)... (PRWEB) , ... August 14, 2017 , ... ... characterized and performing antibodies. Key researchers in the antibody community have recently come ... and consistency for antibodies in the laboratory. , The team at ...
Breaking Biology Technology:
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/13/2017)... 2017 UBM,s Advanced Design and Manufacturing event ... emerging and evolving technology through its 3D Printing and ... alongside the expo portion of the event and feature ... focused on trending topics within 3D printing and smart ... event will take place June 13-15, 2017 at the Jacob ...
Breaking Biology News(10 mins):